<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423410</url>
  </required_header>
  <id_info>
    <org_study_id>EPC2006-04</org_study_id>
    <nct_id>NCT00423410</nct_id>
  </id_info>
  <brief_title>A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer</brief_title>
  <official_title>A First In Man Phase I Study Of EPC2407, A Microtubule Inhibitor Anti-Cancer Drug With Tumor Vascular Endothelial Disrupting Activity: Intravenous Administration Daily For Three Days In Patients With Advanced Solid Tumors And Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EpiCept Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EpiCept Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, pharmacokinetics (PK), and pharmacodynamic effects of a&#xD;
      novel anti-cancer drug, EPC2407, administered to patients with advanced cancer which have not&#xD;
      responded to or have recurred following treatment with available therapies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, open label, multicenter, dose-escalation, safety, pharmacokinetic, and&#xD;
      pharmacodynamic study of EPC2407 administered intravenously over 60 minutes on a QDx3&#xD;
      schedule repeated every 21 days. Patients are enrolled and dosed at the level defined by the&#xD;
      escalation scheme. The primary goal of the study design is to assess toxicity at the fixed&#xD;
      dose levels according to the modified Fibonacci schema.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Duration of drug exposure</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>EPC2407 (crinobulin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPC2407 (crinobulin)</intervention_name>
    <description>IV infusion 1 to 4 hours</description>
    <arm_group_label>EPC2407 (crinobulin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed solid tumor or lymphoma,which has progressed&#xD;
             on standard therapies, for which effective therapy is not available or for patients&#xD;
             who are unwilling to undergo such therapies.&#xD;
&#xD;
          2. Males and Females at least 18 years of age&#xD;
&#xD;
          3. Laboratory data as specified below (according to the site's clinical laboratory ranges&#xD;
             for normal):&#xD;
&#xD;
             i. Hematology: ANC &gt;1500 cells/mm3, platelet count &gt;100,000 cells/mm3 and Hemoglobin &gt;&#xD;
             9 gm/L ii. Hepatic: Direct bilirubin &lt;1.5 X ULN; alanine aminotransferase (ALT) or&#xD;
             aspartate aminotransferase (AST) &lt; 2.5 X ULN. For patients with known liver metastases&#xD;
             or liver neoplasms: alanine aminotransferase (ALT) or aspartate aminotransferase (AST)&#xD;
             &lt; 5.0 X ULN iii. Renal: serum creatinine WNL or creatinine clearance &gt;60 mL/min&#xD;
&#xD;
          4. 12-lead electrocardiogram (ECG) QT intervals: QTc ≤ 450 msec for men and ≤ 470 msec&#xD;
             for women.&#xD;
&#xD;
          5. Estimated life expectancy of at least 3 months&#xD;
&#xD;
          6. ECOG Performance Status &lt; or = 1&#xD;
&#xD;
          7. Previously treated CNS disease allowed if treatment completed and stable for 4 weeks.&#xD;
&#xD;
          8. For men and women of child-producing potential - willingness to employ appropriate&#xD;
             contraceptive methods (including abstinence) during the study&#xD;
&#xD;
          9. Ability to understand the requirements of the study, provide written informed consent&#xD;
             and authorization of use and disclosure of protected health information, and agree to&#xD;
             abide by the study restrictions and to return for the required assessments&#xD;
&#xD;
         10. Cardiac ejection fraction ≥50% by 2D Echocardiogram or &gt; institutional lower limits of&#xD;
             normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant or nursing&#xD;
&#xD;
          2. Radiotherapy or any chemotherapy within the previous 21 days or five half lives of&#xD;
             prior drug (whichever is shorter). See also exclusion #4 below for patients at risk&#xD;
             for cardiac toxicity. Recovery to Grade 1 or less from chemotherapy-induced toxic&#xD;
             effect, except alopecia, is required.&#xD;
&#xD;
          3. Major surgery within the last 4 weeks or minor surgery within the last 2 weeks&#xD;
&#xD;
          4. Significant risk of cardiac drug toxicity due to any of the following: a) Active New&#xD;
             York Heart Association Class III or IV, b) history of or current congestive heart&#xD;
             failure, c) history of myocardial infarction within the last 6 months or ongoing&#xD;
             unstable angina, or anthracycline exposure per exclusion #5.&#xD;
&#xD;
          5. Anthracycline exposure exceeding a cumulative dose of 360 mg/m²&#xD;
&#xD;
          6. Known and ongoing HIV, Hepatitis B or Hepatitis C infection&#xD;
&#xD;
          7. Concomitant use of strong inhibitors of the liver microsomal enzymes CYP2C8, CYP2C9,&#xD;
             CYP2C19 and CYP3A4.&#xD;
&#xD;
          8. Participation in concurrent study of an investigational agent or device&#xD;
&#xD;
          9. Any other condition including but not limited to major co-morbidities, which in the&#xD;
             opinion of the investigator would render the patient ineligible&#xD;
&#xD;
         10. O2 Saturation by pulse oximetry at rest &lt; 90%&#xD;
&#xD;
         11. Concomitant use of drugs that have significant risk of Torsades de Pointes will also&#xD;
             be prohibited. Please refer to drugs listed under &quot;Drugs with Risk of Torsades de&#xD;
             Pointes&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tower Oncology Research</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rebecca and John Moores UCSD Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>January 16, 2007</study_first_submitted>
  <study_first_submitted_qc>January 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <last_update_submitted>September 9, 2009</last_update_submitted>
  <last_update_submitted_qc>September 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Stephane Allard, MD</name_title>
    <organization>Chief medical officer, EpiCept</organization>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Tumor</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

